New Delhi: The Drugs Controller General of India (DCGI) on January 28 granted permission to Bharat Biotech to start conducting booster dose trials for its intranasal coronavirus vaccine, a news agency reported.
The trials will be conducted at nine different sites by Bharat Biotech — the makers of Covaxin.
Bharat Biotech had received regulatory approval for mid-to-late-stage trials for its intranasal vaccine BBV154 in August last year.
The vaccine maker submitted the late-stage trial application to the Drugs Controller General of India in December 2021 stating that an intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns.
The development came a day after the Central Drugs Standard Control Organisation (CDSCO) upgraded the permission for COVAXIN and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions.
